← Back to Search

Procedure

Sernova Cell Pouch for Type 1 Diabetes

Phase 1 & 2
Recruiting
Led By Piotr Witkowski, MD, PhD
Research Sponsored by Sernova Corp
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Clinical history compatible with Type 1 Diabetes Mellitus (T1DM) with onset of disease at <40 years of age, insulin-dependence for ≥5 years at the time of consent, and a sum of patient age and insulin dependent diabetes duration of ≥28
Male and female patients 18 to 65 years of age
Must not have
Untreated proliferative diabetic retinopathy
Presence of colostomy/ileostomy, incisional hernia or other deformity of the abdominal wall precluding implantation of the Cell Pouch
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from day 0 to 90±5 ; day 90±5 to day 180±5; day 180±5 to day 365±14 following final cell pouch transplant and/or last transplant
Awards & highlights

Summary

This trial tests the safety and effectiveness of the Cell Pouch, an implantable device for people with Type 1 Diabetes who struggle with severe low blood sugar. The device holds insulin-producing cells in a natural, blood-rich environment to help them survive and function well. The study will monitor patients over several years to ensure the treatment is safe and works as intended.

Who is the study for?
Adults aged 18-65 with Type 1 Diabetes Mellitus, hypoglycemia unawareness, and severe hypoglycemic episodes can join. They must be under intensive diabetes management and have no stimulated c-peptide response. Exclusions include kidney issues, substance abuse, severe heart disease, uncontrolled lipid levels, certain infections or cancers, immunosuppressive treatments, high HbA1c levels or blood pressure, previous transplants (pancreas/islet), allergies to polymers and those not using contraception.
What is being tested?
The trial is testing the Cell Pouch™ implanted with insulin-producing cells for treating Type 1 Diabetes in patients who don't sense low blood sugar well. The device aims to create a natural environment for cell transplant and function within the body by forming tissue chambers that support engraftment of these cells.
What are the potential side effects?
Potential side effects may include reactions at the implant site such as pain or infection; immune responses against the implanted cells; low blood sugar if insulin production exceeds need; potential complications from surgery like bleeding or clotting.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I was diagnosed with Type 1 Diabetes before 40, have been on insulin for 5+ years, and my age plus years with diabetes is 28 or more.
Select...
I am between 18 and 65 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have diabetic eye disease that hasn't been treated.
Select...
I do not have a colostomy/ileostomy, hernia, or other abdominal wall issues that would prevent implant surgery.
Select...
I have no cancer history, except for treated skin cancer.
Select...
I have high blood pressure in the veins of my liver.
Select...
I am not on any immunosuppressive treatments currently.
Select...
My kidney function is reduced.
Select...
I do not have severe heart issues or uncontrolled blood and liver conditions.
Select...
I do not have severe ongoing stomach issues that affect my medication absorption.
Select...
My donor for islet cells did not have a heart attack and is not high-risk.
Select...
I am taking blood thinners other than aspirin, or my blood clotting time is longer than normal.
Select...
I have a history of severe high blood pressure or conditions that prevent me from having general anesthesia.
Select...
I do not have, nor have I had, infections like hepatitis B/C, HIV, or TB.
Select...
I have not received treatment for Graves' disease.
Select...
I have had an islet transplant before.
Select...
I need more than 1.0 IU/kg/day of insulin.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from day 0 to 90±5 ; day 90±5 to day 180±5; day 180±5 to day 365±14 following final cell pouch transplant and/or last transplant
This trial's timeline: 3 weeks for screening, Varies for treatment, and from day 0 to 90±5 ; day 90±5 to day 180±5; day 180±5 to day 365±14 following final cell pouch transplant and/or last transplant for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
To assess the safety of the Cell Pouch following implantation, and islet transplantation, by evaluating the incidence and severity of adverse events (AEs) determined to be probable or highly probable to the Cell Pouch
Secondary study objectives
Proportion of participants with a reduction in HbA1c >1mg%
Hypoglycemia
Survival of endocrine tissue in the Cell Pouch (defined by positive staining of islets during histological analysis)

Trial Design

1Treatment groups
Experimental Treatment
Group I: T1D Cell Pouch RecipientsExperimental Treatment1 Intervention
Eligible Type 1 Diabetes Mellitus (T1D) subjects with hypoglycemia unawareness and a history of severe hypoglycemic episodes undergoing Sernova Cell Pouch intervention

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The primary treatments for Type 1 Diabetes include insulin therapy, islet cell transplantation, and investigational approaches like the Cell Pouch™. Insulin therapy involves administering exogenous insulin to manage blood glucose levels, compensating for the body's inability to produce insulin. Islet cell transplantation involves transplanting functional islet cells into the patient to restore insulin production. The Cell Pouch™ is a novel scaffold implanted into the body to create a natural, vascularized environment for transplanted islet cells, promoting their engraftment and long-term function. These treatments are crucial for T1D patients as they aim to restore normal insulin production and regulation, reducing the risk of severe hypoglycemic episodes and improving overall glucose control.

Find a Location

Who is running the clinical trial?

CTI Clinical Trial and Consulting ServicesOTHER
35 Previous Clinical Trials
3,777 Total Patients Enrolled
ICON plcIndustry Sponsor
85 Previous Clinical Trials
28,448 Total Patients Enrolled
University of ChicagoOTHER
1,039 Previous Clinical Trials
757,418 Total Patients Enrolled

Media Library

Sernova Cell Pouch™ (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT03513939 — Phase 1 & 2
Type 1 Diabetes Research Study Groups: T1D Cell Pouch Recipients
Type 1 Diabetes Clinical Trial 2023: Sernova Cell Pouch™ Highlights & Side Effects. Trial Name: NCT03513939 — Phase 1 & 2
Sernova Cell Pouch™ (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03513939 — Phase 1 & 2
~1 spots leftby Apr 2025